Cargando…

Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer

BACKGROUND: Osimertinib is an irreversible tyrosine kinase inhibitor approved for the treatment of metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In clinical trials, osimertinib has exhibited excellent activity and less toxicity compared to gefitinib,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Marino, Pietro, Chiapperino, Cosima, Primavera, Francesca Chiara, Martino, Maria Teresa, Brocco, Davide, Carella, Consiglia, Grassadonia, Antonino, Tinari, Nicola, De Tursi, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012497/ https://www.ncbi.nlm.nih.gov/pubmed/35431558 http://dx.doi.org/10.2147/OTT.S315385

Ejemplares similares

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
por: Di Marino, Pietro, et al.
Publicado: (2020)

Breast Cancer “Tailored Follow-up” in Italian Oncology Units: A Web-Based Survey
por: Natoli, Clara, et al.
Publicado: (2014)

Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer
por: Brocco, Davide, et al.
Publicado: (2022)

The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective
por: Brocco, Davide, et al.
Publicado: (2020)

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
por: Grassadonia, Antonino, et al.
Publicado: (2018)

Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review
por: Grassadonia, Antonino, et al.
Publicado: (2015)

Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Correction: Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
por: Grassadonia, Antonino, et al.
Publicado: (2019)

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review
por: Sperduti, Isabella, et al.
Publicado: (2013)

Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates
por: De Lellis, Laura, et al.
Publicado: (2021)

A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression
por: Peri, Marta, et al.
Publicado: (2019)

Exosomes as Pleiotropic Players in Pancreatic Cancer
por: De Lellis, Laura, et al.
Publicado: (2021)

Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors
por: Brocco, Davide, et al.
Publicado: (2021)

Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report
por: Gambale, Elisabetta, et al.
Publicado: (2017)

Prognostic value of gender and primary tumor location in metastatic colon cancer
por: Grassadonia, Antonino, et al.
Publicado: (2023)

Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2022)

High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study
por: Brocco, Davide, et al.
Publicado: (2022)

Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts
por: De Tursi, Michele, et al.
Publicado: (2017)

Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment
por: Buttitta, Fiamma, et al.
Publicado: (2020)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice
por: Angelucci, Domenico, et al.
Publicado: (2012)

EGFR G796D mutation mediates resistance to osimertinib
por: Zheng, Di, et al.
Publicado: (2017)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study
por: Cortellini, Alessio, et al.
Publicado: (2020)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation
por: Brocco, D., et al.
Publicado: (2019)

Corrigendum to “Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation”
por: Brocco, D., et al.
Publicado: (2020)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

Pancytopenia associated with clonazepam
por: Bautista-Quach, Marnelli A, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ej1608rrl8ibp6i8hafub6dnsh